March 11, 2024 article on Genting/TauRx interviewing two genting analysts : https://theedgemalaysia.com/node/704204
When contacted, its analyst Samuel Yin Shao Yang explained that his target price for Genting is now maintained at RM5.73, and the additional potential upside of RM3.67 or 64% — based on RM9.40 — is pending until more clarity from the respective regulatory authorities including US FDA and European Medicines Agency.
Yin noted that HMTM is eligible for fast track consideration by regulators such as FDA. With that, he is hopeful that TauRx’s HMTM drug will get approval by year end. After ascribing 60% discount, TauRx accounts for only nine sen out of its target price of RM5.73 for Genting.